<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="720">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 13, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00905632</url>
  </required_header>
  <id_info>
    <org_study_id>1241.7</org_study_id>
    <secondary_id>2008-008292-34</secondary_id>
    <nct_id>NCT00905632</nct_id>
  </id_info>
  <brief_title>4 Week Combination of BI 207127 NA With Peg-IFN and Ribavirin in Chronic HCV Patients</brief_title>
  <official_title>Safety, Antiviral Activity, and Pharmacokinetics of BI 207127 NA Administered in Combination With Peg-IFN and Ribavirin in Chronic HCV-infected Patients for 4 Weeks, a Randomised, Double-blind, Placebo Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <authority>France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)</authority>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <authority>Switzerland: Swissmedic</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this clinical trial with BI 207127 is to see the effect of 4 week
      combination of BI 207127 with Peginterferon alfa (Peg-IFN) and Ribavirin (RBV) on hepatitis
      C virus (HCV) virus load and how safe BI 207127 is in this combination in HCV infected
      patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The primary efficacy endpoint is virologic response defined as &gt;= 3 log drop in viral load from baseline at day 28 with no evidence of virologic rebound during these 28 days. Virologic rebound is defined as &gt;= 1 log increase in viral load from nadir.</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>early virological response</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>end of treatment response</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sustained virological response</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration time profiles of BI 207127 and CD 6168</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rapid virological response</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety (vital signs, adverse events, safety laboratory tests, ECG)</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral load (Log10) at each visit up to day 28, both actual and change from baseline</measure>
    <time_frame>Baseline up to day 28</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic response at day 28, defined as achieving viral load below the limit of quantification (BLQ) at day 28</measure>
    <time_frame>day 28</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of first day of BI 207127 and CD 6168</measure>
    <time_frame>day 1</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of first day of BI 207127 and CD 6168</measure>
    <time_frame>day 1</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-6 of first day of BI 207127 and CD 6168</measure>
    <time_frame>day 1</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cpre,1 of first day of BI 207127 and CD 6168</measure>
    <time_frame>day 1</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cpre,2 of first day of BI 207127 and CD 6168</measure>
    <time_frame>day 1</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cpre Pharmacokinetic parameter of BI 207127 and CD 6168</measure>
    <time_frame>days 2, 4, 8, 15, 22 and 27</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax,ss Pharmacokinetic parameters of BI 207127 and CD 6168 at steady state after the last dose</measure>
    <time_frame>day 28</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax,ss Pharmacokinetic parameters of BI 207127 and CD 6168 at steady state after the last dose</measure>
    <time_frame>day 28</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C6,ss Pharmacokinetic parameters of BI 207127 and CD 6168 at steady state after the last dose</measure>
    <time_frame>day 28</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-6,ss Pharmacokinetic parameters of BI 207127 and CD 6168 at steady state after the last dose</measure>
    <time_frame>day 28</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-infinity,ss Pharmacokinetic parameters of BI 207127 and CD 6168 at steady state after the last dose</measure>
    <time_frame>day 28</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>λz Pharmacokinetic parameters of BI 207127 and CD 6168 at steady state after the last dose</measure>
    <time_frame>day 28</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2,ss Pharmacokinetic parameters of BI 207127 and CD 6168 at steady state after the last dose</measure>
    <time_frame>day 28</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRTpo,ss Pharmacokinetic parameters of BI 207127 and CD 6168 at steady state after the last dose</measure>
    <time_frame>day 28</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RA,Cmax Pharmacokinetic parameters of BI 207127 and CD 6168 at steady state after the last dose</measure>
    <time_frame>day 28</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with changes in Vital signs (pulse rate, systolic and diastolic blood pressure)</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with changes in body temperature</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with changes in electrocardiogram (ECG)</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with changes in safety laboratory test</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and Intensity of Adverse events</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with Discontinuations due to AEs</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with changes in Physical examination</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Assessment of tolerability</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <arm_group>
    <arm_group_label>BI 207127 low dose + SOC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BI 207127 low dose tid + SOC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 207127 middle dose +SOC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BI 207127 middle dose tid + SOC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 207127 high dose+SOC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BI 207127 high dose tid +SOC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + SOC</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tid +SOC</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 207127 middle dose +SOC</intervention_name>
    <description>BI 207127 middle dose tid + SOC</description>
    <arm_group_label>BI 207127 middle dose +SOC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 207127 high dose+SOC</intervention_name>
    <description>BI 207127 high dose tid +SOC</description>
    <arm_group_label>BI 207127 high dose+SOC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo + SOC</intervention_name>
    <description>Placebo tid +SOC</description>
    <arm_group_label>Placebo + SOC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 207127 low dose + SOC</intervention_name>
    <description>BI 207127 low dose tid + SOC</description>
    <arm_group_label>BI 207127 low dose + SOC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. HCV genotype 1

          2. HCV viral load &gt;100,000 IU/mL

          3. histology or fibroscan to rule out cirrhosis

          4. Absence of retinopathy

          5. treatment naive patients and treatment experienced patients

          6. Age 18 - 70 years

          7. Male OR female with documented hysterectomy OR postmenopausal

        Exclusion criteria:

          1. Fertile males not willing to use an adequate form of contraception

          2. Pretreatment with any HCV-polymerase inhibitor

          3. Any concurrent disease if clinically significant based on the investigator's medical
             assessment

          4. Current alcohol or drug abuse, or history of the same

          5. Positive test for HIV or HBs

          6. History of malignancy

          7. Planned or concurrent usage of any other pharmacological therapy including any
             antiviral therapy or vaccination

          8. Usage of any investigational drug within thirty (30) days prior to enrolment or 5
             halflives, whichever is longer

          9. Any clinically significant laboratory abnormalities based on the investigator's
             medical assessment at screening

         10. Patients treated with any interferon (approved or investigational) or Peg-IFN and/or
             Ribavirin within 3 months prior to screening

         11. Known hypersensitivity to drugs or excipients; Further exclusion criteria apply
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1241.7.3307A CHU de Grenoble</name>
      <address>
        <city>Grenoble cédex 9</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1241.7.3303A Hôpital Claude Huriez</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1241.7.3302A Hopital de l'Hotel Dieu</name>
      <address>
        <city>Lyon cedex 02</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1241.7.3301A Hôpital Saint Eloi</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1241.7.3305A HOP Archet 2</name>
      <address>
        <city>Nice Cedex 3</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1241.7.3306A Hôpital Haut-Lévêque</name>
      <address>
        <city>Pessac Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1241.7.3304A HOP de Brabois</name>
      <address>
        <city>Vandoeuvre</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1241.7.49010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aachen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1241.7.49012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1241.7.49004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1241.7.49011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1241.7.49001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1241.7.49013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1241.7.49009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Regensburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1241.7.49002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1241.7.41003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Basel</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1241.7.41004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lugano</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1241.7.41001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Gallen</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <lastchanged_date>November 21, 2014</lastchanged_date>
  <firstreceived_date>May 19, 2009</firstreceived_date>
  <responsible_party>
    <name_title>Boehringer Ingelheim, Study Chair</name_title>
    <organization>Boehringer Ingelheim</organization>
  </responsible_party>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
